News

The latest on managing care, value-based care, insurance markets, payers & providers

Adding fuel to an already raging debate about right-to-try drugs, a company called Brainstorm Cell Therapeutics is developing an experimental drug for terminal patients who have Lou Gehrig’s disease (amyotrophic lateral sclerosis) and that drug won’t be cheap. The new drug is called NurOwn. The…
It seems as if reports of the ACA’s demise have been greatly exaggerated. The Wall Street Journal reports today that after years of pulling out of the Obamacare marketplaces, health insurance plans have started to re-enter. That’s in part because the health plans are starting to make money because…
Peter Wehrwein
Atul Gawande is a splashy choice to head up the Amazon–Berkshire Hathaway–JP Morgan Chase health care initiative. Stat called the 52-year-old surgeon, Harvard professor, and prolific New Yorker staff writer an “all-around health care celebrity.” Gawande is royalty in Boston’s high-powered…
Small employers can more effectively ban together to buy health insurance under rules unveiled yesterday by the Trump administration that loosens restrictions on association health plans (AHPs). That means that small companies can now buy insurance in the same market as larger companies. “This reform…
The FDA has approved the first generic versions of Suboxone (buprenorphine and naloxone, Indivior PLC) sublingual film for the treatment of opioid dependence. “The FDA is taking new steps to advance the development of improved treatments for opioid use disorder and to make sure these medicines are…
When terminally ill Americans receive experimental medicines through so-called “compassionate use” programs, they typically only get these drugs after extensive tests for safety and effectiveness, a recent study suggests. “This means that sufficient evidence of safety and effectiveness has been…
The Medicines Development for Global Health (MDGH) and the World Health Organization Special Program for Research and Training in Tropical Diseases (TDR) have announced that the FDA has approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients 12 years of age and…
Valeant Pharmaceuticals' plans to grow its dermatology business hit a snag this week, when the specialty drug-maker disclosed that the FDA had declined to approve an experimental psoriasis treatment key to the unit's turnaround, according to a BioPharma Divereport.  The regulator issued a complete…